| pubmed-article:21619673 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21619673 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:21619673 | lifeskim:mentions | umls-concept:C0032659 | lld:lifeskim |
| pubmed-article:21619673 | lifeskim:mentions | umls-concept:C0002895 | lld:lifeskim |
| pubmed-article:21619673 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:21619673 | lifeskim:mentions | umls-concept:C0020402 | lld:lifeskim |
| pubmed-article:21619673 | lifeskim:mentions | umls-concept:C0851347 | lld:lifeskim |
| pubmed-article:21619673 | lifeskim:mentions | umls-concept:C0040808 | lld:lifeskim |
| pubmed-article:21619673 | lifeskim:mentions | umls-concept:C1527178 | lld:lifeskim |
| pubmed-article:21619673 | pubmed:dateCreated | 2011-6-20 | lld:pubmed |
| pubmed-article:21619673 | pubmed:abstractText | Hydroxyurea (HU) is the first approved pharmacological treatment of sickle cell anemia (SCA). The objectives of this study were to develop population pharmacokinetic(PK)-pharmacodynamic(PD) models for HU in order to characterize the exposure-efficacy relationships and their variability, compare two dosing regimens by simulations and develop some recommendations for monitoring the treatment. | lld:pubmed |
| pubmed-article:21619673 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21619673 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21619673 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21619673 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21619673 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21619673 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21619673 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21619673 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21619673 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21619673 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21619673 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21619673 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21619673 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21619673 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21619673 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21619673 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21619673 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21619673 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21619673 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21619673 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21619673 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21619673 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21619673 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21619673 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21619673 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21619673 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21619673 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21619673 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21619673 | pubmed:issn | 1750-1172 | lld:pubmed |
| pubmed-article:21619673 | pubmed:author | pubmed-author:TodMichelM | lld:pubmed |
| pubmed-article:21619673 | pubmed:author | pubmed-author:BachirDoraD | lld:pubmed |
| pubmed-article:21619673 | pubmed:author | pubmed-author:GalactérosFré... | lld:pubmed |
| pubmed-article:21619673 | pubmed:author | pubmed-author:HulinAnneA | lld:pubmed |
| pubmed-article:21619673 | pubmed:author | pubmed-author:GirardPascalP | lld:pubmed |
| pubmed-article:21619673 | pubmed:author | pubmed-author:HabibiAnoosha... | lld:pubmed |
| pubmed-article:21619673 | pubmed:author | pubmed-author:SassiHindH | lld:pubmed |
| pubmed-article:21619673 | pubmed:author | pubmed-author:PauleInesI | lld:pubmed |
| pubmed-article:21619673 | pubmed:author | pubmed-author:PhamKim PdKP | lld:pubmed |
| pubmed-article:21619673 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21619673 | pubmed:volume | 6 | lld:pubmed |
| pubmed-article:21619673 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21619673 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21619673 | pubmed:pagination | 30 | lld:pubmed |
| pubmed-article:21619673 | pubmed:meshHeading | pubmed-meshheading:21619673... | lld:pubmed |
| pubmed-article:21619673 | pubmed:meshHeading | pubmed-meshheading:21619673... | lld:pubmed |
| pubmed-article:21619673 | pubmed:meshHeading | pubmed-meshheading:21619673... | lld:pubmed |
| pubmed-article:21619673 | pubmed:meshHeading | pubmed-meshheading:21619673... | lld:pubmed |
| pubmed-article:21619673 | pubmed:meshHeading | pubmed-meshheading:21619673... | lld:pubmed |
| pubmed-article:21619673 | pubmed:meshHeading | pubmed-meshheading:21619673... | lld:pubmed |
| pubmed-article:21619673 | pubmed:meshHeading | pubmed-meshheading:21619673... | lld:pubmed |
| pubmed-article:21619673 | pubmed:meshHeading | pubmed-meshheading:21619673... | lld:pubmed |
| pubmed-article:21619673 | pubmed:meshHeading | pubmed-meshheading:21619673... | lld:pubmed |
| pubmed-article:21619673 | pubmed:meshHeading | pubmed-meshheading:21619673... | lld:pubmed |
| pubmed-article:21619673 | pubmed:meshHeading | pubmed-meshheading:21619673... | lld:pubmed |
| pubmed-article:21619673 | pubmed:meshHeading | pubmed-meshheading:21619673... | lld:pubmed |
| pubmed-article:21619673 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21619673 | pubmed:articleTitle | Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen. | lld:pubmed |
| pubmed-article:21619673 | pubmed:affiliation | Université de Lyon, Lyon, France. | lld:pubmed |
| pubmed-article:21619673 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21619673 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:21619673 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
